Risk of venous thromboembolism with drospirenone in combined oral contraceptive products
N Sehovic, KP Smith - Annals of Pharmacotherapy, 2010 - journals.sagepub.com
OBJECTIVE: To review primary literature regarding the risk of venous thromboembolism
(VTE) in users of combined oral contraceptives (COCs) containing drospirenone compared …
(VTE) in users of combined oral contraceptives (COCs) containing drospirenone compared …
[HTML][HTML] Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at …
TL de Morais, C Giribela, MG Nisenbaum… - European Journal of …, 2014 - Elsevier
The use of combined oral contraceptives is widespread among hypertensive women despite
being associated with increased cardiovascular risk. Contraceptives containing …
being associated with increased cardiovascular risk. Contraceptives containing …
Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data.
DF Archer - The Journal of Reproductive Medicine, 2007 - europepmc.org
A novel progestogen, drospirenone, in combination with 17beta-estradiol has been studied
as hormone therapy (HT) for menopausal symptoms. In addition to providing effective and …
as hormone therapy (HT) for menopausal symptoms. In addition to providing effective and …
Safety of a new oral contraceptive containing drospirenone
LAJ Heinemann, J Dinger - Drug safety, 2004 - Springer
New chemical entities must undergo rigorous, and preferably independent, safety and
efficacy assessments before entry into the market. This is also true for oral contraceptives …
efficacy assessments before entry into the market. This is also true for oral contraceptives …
A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20μg and drospirenone 3mg with a 21-day regimen of …
DM Gruber, JC Huber, GB Melis, C Stagg… - Treatments in …, 2006 - Springer
Objective: To compare the cycle control, efficacy, and safety of a new low-dose combined
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg with an …
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg with an …
The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function
K Skórzewska, S Radowicki… - Ginekologia …, 2009 - journals.viamedica.pl
Introduction: Application of older generations of progestins used in oral contraceptives may
increase the risk of cardiovascular diseases (CVD) because of negative impact on lipids …
increase the risk of cardiovascular diseases (CVD) because of negative impact on lipids …
An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg …
W Suthipongse, S Taneepanichskul - Contraception, 2004 - Elsevier
This study was conducted to compare the cycle control, efficacy and adverse events of a
new low-dose oral contraceptive pill regimen containing 3 mg drospirenone (DRSP)/30 μg …
new low-dose oral contraceptive pill regimen containing 3 mg drospirenone (DRSP)/30 μg …
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase
D Apter, E Colli, K Gemzell-Danielsson, K Peters - Contraception, 2020 - Elsevier
Objective To assess the safety, tolerability and bleeding patterns of drospirenone 4.0 mg.
Study design A multicenter, open-label, safety trial in sexually-active adolescents aged 12 …
Study design A multicenter, open-label, safety trial in sexually-active adolescents aged 12 …
Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol
C Kluft, Y Zimmerman, M Mawet, C Klipping… - Contraception, 2017 - Elsevier
Objective The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone
(DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG) …
(DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG) …
[HTML][HTML] Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal …
P Villa, R Suriano, L Ricciardi, V Tagliaferri… - Fertility and sterility, 2011 - Elsevier
OBJECTIVE: To evaluate the effects of a daily E2 (1 mg) plus drospirenone oral formulation
(2 mg) on glycoinsulinemic metabolism, lipid profile, and endothelial function in symptomatic …
(2 mg) on glycoinsulinemic metabolism, lipid profile, and endothelial function in symptomatic …